Xenetic Biosciences to Hold Business Update Conference Call September 23 at 6:00 a.m. Eastern Time
Xenetic Biosciences Announces Ongoing Safety and Efficacy Data From Phase 2 Trial of ErepoXen(R)
Xenetic Biosciences Announces Ongoing Safety Data From Phase 2 Trial of ErepoXen(R)
Xenetic Biosciences Announces Dosing of First Patient on Dialysis in Phase 2a Clinical Study of ErepoXen(R)
Xenetic Biosciences Strengthens Technology Patent Portfolio
Xenetic Biosciences to Present at the Third Annual Marcum MicroCap Conference
Xenetic Biosciences Announces First Quarter 2014 Financial Results and Business Update
Xenetic Biosciences Announces Positive Phase 1 Clinical Results for PSA-Oxyntomodulin for the Treatment of Type II Diabetes and Obesity
Xenetic Biosciences Appoints Industry Veteran Mark Leuchtenberger as Chairman of the Board of Directors
